Market Research Logo

Prostate Cancer: Update Bulletin [Feb 2016]

Prostate Cancer: Update Bulletin [Feb 2016]


Gain new KOL insights on the latest events with the potential to shape the targeted treatment of Prostate Cancer (PC). Topics covered include opinions about the role of custirsen (OGX-011; OncoGenex/Teva) in combination with Jevtana (cabazitaxel; Sanofi) as a second-line treatment for metastatic castrate-resistant PC (mCRPC), and the development of Lynparza (olaparib; AstraZeneca) as a treatment for BRCA1/2 or ATM gene mutated mCRPC in patients who have received prior taxane-based chemotherapy and Zytiga (abiraterone acetate; Johnson & Johnson), or Xtandi (enzalutamide; Astellas/Medivation). The UK’s National Institute for Health and Clinical Excellence’s (NICE) recommendations concerning the use of Xtandi and Zytiga for treating mCRPC in a pre-chemotherapy setting are also discussed.

Key Questions Answered in this Update Bulletin:

  • Do the lacklustre results from the interim analysis of the Phase III AFFINITY trial spell the end for custirsen as a mCRPC therapy?
  • While the TOPARP study confirms Lynparza’s activity in BRCA1/2 and ATM gene mutated mCRPC, how likely is it that the agent will be utilised in a wider prostate cancer patient population?
  • How do KOLs view the recommendations published by the UK’s National Institute for Health and Clinical Excellence (NICE) that Xtandi, but not Zytiga, should be used to treat patients with mCRPC in the pre-chemotherapy setting?
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

Please Note: Due to the brevity and/or nature of the content posted, there is no table of contents available for this report.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report